-
Mashup Score: 2Program Guide – ASCO Meeting Program Guide - 5 month(s) ago
Nathan W. Sweeney HealthTree, Lehi, UT Nathan W. Sweeney, Jenny Ahlstrom, Michael A. Thompson HealthTree, Lehi, UT, CrowdCare Foundation, Draper, UT, Aurora Cancer Care, Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI Takeda, Sanofi and GSK for HealthTree Background: Multiple myeloma (MM) prognostic risk factors include cancer genetics as well as imaging characteristics. In order to engage the patient (pt) community regarding genetic testing and diagnostic imaging we utilized a patient-cen
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - Breast - ASTRO 2023: Nipple-Preserving Radiotherapy After Surgery for Breast Cancer - 5 month(s) ago
By continuing to browse this site you permit us and our partners to place identification cook ies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - Prostate - ASTRO 2023: Fewer, Higher Doses of SBRT for Localized Prostate Cancer - 5 month(s) ago
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for mar keting. Read our Privacy Policy to learn
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0OPPORTUNISTIC EVALUATION OF BONE MINERAL DENSITY BY PET-CT IN HODGKIN LYMPHOMA PATIENTS - PubMed - 6 month(s) ago
Objective: Bone density loss and increased risk for osteoporosis are of concern in Hodgkin lymphoma (HL) patients. Routinely performed positron emission tomography-computed tomography (PET-CT) scans could be informative in assessing bone mineral density (BMD). Methods: Th …
Source: pubmed.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma - 7 month(s) ago
PURPOSE Total neoadjuvant therapy (TNT) is a newly established standard treatment for rectal adenocarcinoma. Current methods to communicate magnitudes of regression during TNT are subjective and imprecise. Magnetic resonance tumor regression grade (MR-TRG) is an existing, but rarely used, regression grading system. Prospective validation of MR-TRG correlation with pathologic response in patients undergoing TNT is lacking. Utility of adding diffusion-weighted imaging to MR-TRG is also unknown. METHODS We conducted a multi-institutional prospective imaging substudy within NRG-GI002 (ClinicalTrials.gov identifier: NCT02921256) examining the ability of MR-based imaging to predict pathologic complete response (pCR) and correlate MR-TRG with the pathologic neoadjuvant response score (NAR). Serial MRIs were needed from 110 patients. Three radiologists independently, then collectively, reviewed each MRI for complete response (mriCR), which was tested for positive predictive value (PPV), negati
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3PSMA PET ratio predicts response to [177Lu]PSMA radioligand therapy: a multicenter study - 7 month(s) ago
Jeremie Calais, MD, MSc, University of California, Los Angeles, CA, discusses a retrospective study on PSMA PET tumor–to–salivary gland ratio to predict response to [177Lu]PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy. A total of 237 men were included, and PSG scores were calculated based on quantitative and visual assessments of baseline PSMA PET images. Patients were categorized into high, intermediate, and low PSG score groups. The study found that a higher PSG score was associated with a greater decline in prostate-specific antigen (PSA) levels, longer PSA progression-free survival, and improved overall survival. Both the quantitative and visual PSG scores demonstrated substantial reproducibility and comparable prognostic value. The PSG score can serve as a prognostic tool for predicting treatment response and outcomes in mCRPC patients receiving PSMA-targeted radioligand therapy. This
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
PURPOSE Prospective data suggested a superiority of intraoperative MRI (iMRI) over 5-aminolevulinic acid (5-ALA) for achieving complete resections of contrast enhancement in glioblastoma surgery. We investigated this hypothesis in a prospective clinical trial and correlated residual disease volumes with clinical outcome in newly diagnosed glioblastoma. METHODS This is a prospective controlled multicenter parallel-group trial with two center-specific treatment arms (5-ALA and iMRI) and blinded evaluation. The primary end point was complete resection of contrast enhancement on early postoperative MRI. We assessed resectability and extent of resection by an independent blinded centralized review of preoperative and postoperative MRI with 1-mm slices. Secondary end points included progression-free survival (PFS) and overall survival (OS), patient-reported quality of life, and clinical parameters. RESULTS We recruited 314 patients with newly diagnosed glioblastomas at 11 German centers. A t
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - Prostate - ASCO 2023: Does PSA Nadir After Radiotherapy Impact Outcomes in Localized Prostate Cancer? - 9 month(s) ago
By: Julia Fiederlein Cipriano Posted: Thursday, June 22, 2023 Praful Ravi, MB, BChir, MRCP, of the Dana-Farber Cancer Institute, Boston, and colleagues conducted an analysis to determine the prognostic impact of having a prostate-specific antigen (PSA) nadir of at least 0.1 ng/mL within 6 months of completing…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 9 month(s) ago
AuthorsNathan W. SweeneyHealthTree, Lehi, UTNathan W. Sweeney, Jenny Ahlstrom, Michael A. ThompsonOrganizationsHealthTree, Lehi, UT, CrowdCare Foundation, Draper, UT, Aurora Cancer Care, Aurora Research Institute, Advocate Aurora Health, Milwaukee, WIAbstract DisclosuresResearch FundingPharmaceutical/Biotech CompanyTakeda, Sanofi and GSK for HealthTree Background: Multiple myeloma (MM)…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0RAPID-RT: dose-limited cardio-radiotherapy for NSCLC - 10 month(s) ago
Corinne Faivre-Finn, FRCR, MD, PhD, The University of Manchester, Manchester, UK & The Christie NHS, Manchester, UK, discusses the real-world…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
. @HealthtreeMM Patient Portal mediated myeloma patient reported diagnostic imaging and pathology testing - @NSweeneyPhd @AhlstromJenny @mtmdphd J Clin Oncol 38: 2020 (suppl; abstr e20565) #ASCO20 https://t.co/CRLXETpeMm #mmsm #oncorad #oncopath https://t.co/V1FlI7DNBm